SCHEMBL6677757

SCHEMBL6677757

CCNC(=O)Nc1ccc(Cn2c(=O)[nH]c3c(c2=O)C=C(C(=O)O)CN3C)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 1/20 0.37
POLB P06746 6/20 0.35
RAB9A P51151 3/20 0.35
TP53 P04637 2/20 0.35
NPC1 O15118 1/20 0.35
HDAC6 Q9UBN7 1/20 0.34
MAPT P10636 9/20 0.34
LMNA P02545 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
MTHFD2 P13995 1/20 0.34
KDM4E B2RXH2 3/20 0.33
ALDH1A1 P00352 2/20 0.33
CA12 O43570 1/20 0.33
CA9 Q16790 1/20 0.33
MEN1 O00255 1/20 0.33
ALOX15 P16050 1/20 0.33
KMT2A Q03164 1/20 0.33
NPSR1 Q6W5P4 2/20 0.33
HPGD P15428 2/20 0.33
MAPK1 P28482 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6678347 0.84 ALDH1A1 (0.43) RAB9ALMNASMN1; SMN2KDM4EALDH1A1
SCHEMBL7061233 0.82 ABCB1 (0.35) ABCB1POLBRAB9ATP53NPC1
SCHEMBL6685457 0.82 ABCB1 (0.35) ABCB1POLBRAB9ATP53NPC1
SCHEMBL6678978 0.82 ABCB1 (0.35) ABCB1POLBRAB9ATP53NPC1
SCHEMBL7062180 0.75 MTHFD2 (0.39) ABCB1POLBRAB9ATP53NPC1
SCHEMBL6683636 0.74 PARP1 (0.34) SMN1; SMN2
SCHEMBL6664325 0.74 TRPA1 (0.46) POLBMAPTLMNASMN1; SMN2KDM4E
SCHEMBL6679671 0.70 MMP1 (0.40) MAPTLMNASMN1; SMN2KDM4EALDH1A1
SCHEMBL6664764 0.69 MAPT (0.48) RAB9ATP53MAPTSMN1; SMN2KDM4E
SCHEMBL6683369 0.69 KLKB1 (0.41) POLBLMNAKDM4ERXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors ROARK WILLIAM HOWARD (US) 2004-11-11 US claimed
WO-2004014921-A1 5,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO claimed
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors ROARK WILLIAM HOWARD (US) 2004-11-11 US disclosed
WO-2004014921-A1 5,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors MMP9, MMP13, MMP25 ABCB1 624/4885POLB 127/4885RAB9A 627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.